LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article: Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.

Rocco, Patricia R M / Silva, Pedro L / Cruz, Fernanda F / Tierno, Paulo F G M M / Rabello, Eucir / Junior, Jéfiton Cordeiro / Haag, Firmino / de Ávila, Renata E / da Silva, Joana D G / Mamede, Mariana M S / Buchele, Konrad S / Barbosa, Luiz C V / Cabral, Anna C / Junqueira, Antônio A F / Araújo-Filho, João A / da Costa, Lucianna A T J / Alvarenga, Pedro P M / Moura, Alexandre S / Carajeleascow, Ricardo /
de Oliveira, Mirella C / Silva, Roberta G F / Soares, Cynthia R P / Fernandes, Ana Paula S M / Fonseca, Flavio Guimarães / Camargos, Vidyleison Neves / Reis, Julia de Souza / Franchini, Kleber G / Luiz, Ronir R / Morais, Sirlei / Sverdloff, Carlos / Martins, Camila Marinelli / Felix, Nathane S / Mattos-Silva, Paula / Nogueira, Caroline M B / Caldeira, Dayene A F / Pelosi, Paolo / Lapa-E-Silva, José R

Frontiers in medicine

2022  Volume 9, Page(s) 844728

Abstract: Background: Nitazoxanide exerts antiviral activity : Methods: A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms ...

Abstract Background: Nitazoxanide exerts antiviral activity
Methods: A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical improvement, hospital discharge, oxygen requirements, death, and adverse events within 14 days.
Results: Of the 498 patients, 405 (202 in the nitazoxanide group and 203 in the placebo group) were included in the analyses. Admission to the intensive care unit did not differ between the groups (hazard ratio [95% confidence interval], 0.68 [0.38-1.20],
Conclusions: Nitazoxanide, compared with placebo, did not prevent admission to the intensive care unit for patients hospitalized with COVID-19 pneumonia.
Clinical trial registration: Brazilian Registry of Clinical Trials (REBEC) RBR88bs9x; ClinicalTrials.gov, NCT04561219.
Language English
Publishing date 2022-04-13
Publishing country Switzerland
Document type Journal Article
ZDB-ID 2775999-4
ISSN 2296-858X
ISSN 2296-858X
DOI 10.3389/fmed.2022.844728
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top